TGA approves RSV vax for Australians over 60
Arexvy is 83% effective at preventing RSV-related lower respiratory tract disease.
The TGA has approved the first respiratory syncytial virus vaccine, Arexvy, with sponsor GSK Australia hinting it would “soon” be available on a private script for over-60s.
The company, which first sought approval for the protein-based vaccine in early 2023, said the decision was based on results from its phase III trial involving 25,000 older adults.
